Proposal for VK2809 (Viking Therapeutics)

Overview of Therapeutic Candidate:
VK2809 is a liver‐targeted prodrug belonging to the class of thyroid hormone receptor beta (THRβ) agonists and was originally developed by Viking Therapeutics to treat metabolic liver diseases such as non‐alcoholic steatohepatitis (NASH) (ClinicalTrials.gov, n.d.). This compound is synthesized with a prodrug design that confers preferential activation in the liver, thereby limiting systemic exposure and avoiding off‐target effects on tissues that express THRα, such as the heart and bone (Asgharpour et al., 2021). The chemical design exploits hepatic cytochrome P450 enzymes—primarily CYP3A—to convert VK2809 into its active metabolite, which exhibits high potency for THRβ with an EC50 of approximately 0.24 nM and minimal activity on THRα (Bansal & Karim, 2023). Such an approach is consistent with previous developments in selective THRβ agonists, a therapeutic class that has been explored for lipid lowering in dyslipidemia and metabolic liver disease by enhancing hepatic fatty acid oxidation (Byrne et al., 2024). Historically, thyroid hormone analogues have been synthesized either by chemical modification of natural thyroid hormones—such as triiodothyronine (T3) and thyroxine (T4)—or by creating novel structures that mimic T3’s beneficial effects on metabolism without causing systemic thyrotoxicity (Chui et al., 2024).

Therapeutic History:
Thyroid hormone receptor agonists, particularly those selective for the beta isoform, have been under investigation for several years for their potential to treat metabolic disorders, including non‐alcoholic fatty liver disease (NAFLD) and its inflammatory and fibrotic progression to NASH (Liao et al., 2022). Early agents such as sobetirome (GC-1) and eprotirome showed promise in reducing lipid levels and hepatic steatosis in preclinical studies but were limited by off‐target effects including adverse impacts on cardiac and skeletal tissues (Bansal & Karim, 2023). More recent compounds, including MGL-3196 (resmetirom), have demonstrated significant improvements in liver fat reduction and lipid profiles in phase II and III trials, setting a benchmark for the safety and efficacy profile that newer agents like VK2809 aim to achieve (Karim & Bansal, 2023). VK2809, in contrast with earlier generations, leverages a prodrug strategy specifically intended to improve liver targeting, and early human clinical trials have shown encouraging data with significant reductions in hepatic fat content and favorable safety signals (Viking Therapeutics, Inc., 2016; Bansal & Karim, 2023).

Mechanism of Action:
VK2809 operates through a well-characterized mechanism by selectively activating THRβ receptors that are predominantly expressed in hepatocytes (Byrne et al., 2024). Upon administration, the prodrug is metabolized in the liver by CYP3A enzymes to release its active form, which then binds to THRβ with high affinity, triggering a cascade of intracellular events that include modulation of gene transcription involved in lipid metabolism (Luong et al., 2020). The activated receptor upregulates genes responsible for fatty acid β-oxidation, mitochondrial biogenesis, and autophagy, thereby promoting enhanced mitochondrial fatty acid oxidation and reducing hepatic triglyceride accumulation (Pu et al., 2025). Furthermore, this selective receptor activation decreases de novo lipogenesis and improves cholesterol clearance by upregulating LDL receptors, an effect that is critical in the management of dyslipidemia seen with NASH (Sinha et al., 2025). At the molecular level, gene expression changes in hepatocytes, such as increased levels of CPT1A, DIO1, and ANGPTL4, have been documented following THRβ activation, underscoring the mechanism by which VK2809 exerts its metabolic and anti-steatotic effects (Luong et al., 2020).

Expected Effect:
Preclinical studies in rodent models have demonstrated that VK2809 markedly reduces hepatic triglycerides and improves lipid profiles, which is consistent with increased expression of β-oxidation genes and improved mitochondrial function (Bansal & Karim, 2023). Clinically, treatment with VK2809 has been associated with significant decreases in liver fat content—as measured by imaging modalities such as MRI-proton density fat fraction (MRI-PDFF) in phase II trials—indicating that the compound effectively mitigates hepatic steatosis (Viking Therapeutics, Inc., 2019; Asgharpour et al., 2021). The anticipated effect in cellular assays is an upregulation of genes related to β-oxidation and mitochondrial function in hepatocytes, which in turn leads to diminished lipotoxicity, reduced inflammatory signaling, and potentially decreased fibrosis (Prikhodko et al., 2022). It is expected that in human patients with NASH, VK2809 will not only reduce intrahepatic fat accumulation but also improve surrogate markers of liver injury such as ALT and AST levels, while maintaining a safety profile superior to non-selective thyroid hormone therapies (Bansal & Karim, 2023; ClinicalTrials.gov, n.d.).

Overall Evaluation:
The overall evaluation of VK2809 as a therapeutic candidate for NASH is highly promising and strategically sound based on its unique attributes. Strengths of VK2809 include its liver-targeted prodrug design and high selectivity for THRβ, which collectively ensure that its beneficial effects on lipid metabolism are maximized in the liver while systemic exposure—and consequently adverse effects on the heart, bone, or skeletal muscle—are minimized (Luong et al., 2020). This liver specificity is of paramount importance in NASH, where off-target effects from systemic thyroid hormone activation have previously limited the utility of earlier agents (Prikhodko et al., 2022). In addition, the robust preclinical data demonstrating improvements in hepatic triglyceride levels, enhanced mitochondrial fatty acid oxidation, and beneficial gene expression profiles provide a strong mechanistic rationale for its use (Zhao et al., 2022). Early-phase clinical studies have already shown that VK2809 can significantly reduce liver fat and improve lipid profiles in patients with metabolic-associated fatty liver disease, and these effects compare favorably to those observed with other advanced THRβ agonists like resmetirom (Karim & Bansal, 2023).

Notwithstanding these strengths, there are also some challenges to consider in the continued development of VK2809. One potential weakness is the need for longer-term safety data and confirmation of histologic improvements in liver fibrosis beyond reductions in liver fat content, as current data are based on relatively short-duration trials (Viking Therapeutics, Inc., 2016; Bansal & Karim, 2023). Moreover, while the prodrug design enhances hepatic selectivity, inter-individual variability in cytochrome P450 enzyme activity could potentially affect drug activation and pharmacokinetics in some patients, thereby complicating dose optimization (Zhao et al., 2022). There is also the inherent challenge in using imaging modalities as surrogate markers for NASH improvement, given the complex etiopathogenesis of the disease where inflammation and fibrosis also play critical roles (Petroni et al., 2021). Despite these concerns, the overall safety profile observed thus far has been favorable, with minimal thyroid-related adverse effects reported, which is a critical advancement over earlier non-selective compounds (Rubin et al., 2021).

In summary, the comprehensive literature review indicates that VK2809 exhibits strong potential as a repurposed drug candidate for the treatment of non-alcoholic steatohepatitis. Its synthetic prodrug nature, combined with targeted activation in the liver and selective engagement of THRβ, underpins a well-defined mechanism of action leading to enhanced mitochondrial fatty acid oxidation and reduced hepatic steatosis. The therapeutic history of thyroid hormone receptor agonists in metabolic diseases further supports the strategy of utilizing a liver-directed agent to improve NASH outcomes with reduced systemic side effects (Byrne et al., 2024; Bansal & Karim, 2023). While continued clinical trials are essential to address the longer-term efficacy and potential effects on liver fibrosis and inflammation, the evidence thus far suggests that VK2809 is a highly promising candidate that merits further development in a robust clinical program. The strengths of selective receptor activation, pronounced effects on lipid metabolism, and favorable safety profile make it a leading contender among novel therapeutic approaches for NASH, even as potential challenges such as variability in drug activation and the need for comprehensive histologic endpoints are addressed in subsequent studies (Alkhouri, 2020; Tanase et al., 2020; Zhou et al., 2021).

References:
Alkhouri, N. (2020). Thyromimetics as emerging therapeutic agents for nonalcoholic steatohepatitis: Rationale for the development of resmetirom (MGL-3196). Expert Opinion on Investigational Drugs, 29, 99–101. https://doi.org/10.1080/13543784.2020.1708899

Asgharpour, A., Dinani, A., & Friedman, S. L. (2021). Basic science to clinical trials in non-alcoholic fatty liver disease and alcohol-related liver disease: Collaboration with industry. Translational Gastroenterology and Hepatology, 6, Article 5. https://doi.org/10.21037/tgh.2020.01.04

Bansal, M. B., & Karim, G. (2023). … irom: An oraooy anminis eren, wsmaoo-mooeuuoe, liver-nireu en, β-seoeu ive thh agonis for ce treamen of non-aouocooiu fawy liver disease ann non …. Unknown Journal.

Byrne, C. D., Targher, G., & Tilg, H. (2024). Thyroid hormone receptor-beta agonists: New MASH therapies on the horizon. Gut. Advance online publication. https://doi.org/10.1136/gutjnl-2023-330596

Chui, Z. S. W., Xue, Y., & Xu, A. (2024). Hormone-based pharmacotherapy for metabolic dysfunction-associated fatty liver disease. Medical Review, 4, 158–168. https://doi.org/10.1515/mr-2024-0007

ClinicalTrials.gov. (n.d.). Search terms: VK2809 OR Viking Therapeutics AND (non-alcoholic steatohepatitis OR NASH). Retrieved from https://clinicaltrials.gov

Karim, G., & Bansal, M. B. (2023). Resmetirom: An orally administered, small-molecule, liver-directed, β-selective THR agonist for the treatment of non-alcoholic fatty liver disease and non-alcoholic steatohepatitis. European Endocrinology, 19, 60. https://doi.org/10.17925/ee.2023.19.1.60

Liao, C.-J., Huang, P.-S., Chien, H.-T., Lin, T.-K., Yeh, C.-T., & Lin, K.-H. (2022). Effects of thyroid hormones on lipid metabolism pathologies in non-alcoholic fatty liver disease. Biomedicines, 10, Article 1232. https://doi.org/10.3390/biomedicines10061232

Luong, X. G., Stevens, S. K., Jekle, A., Lin, T.-I., Gupta, K., Misner, D., Chanda, S., Mukherjee, S., Williams, C., Stoycheva, A., Blatt, L. M., Beigelman, L. N., Symons, J. A., Raboisson, P., McGowan, D., Vandyck, K., & Deval, J. (2020). Regulation of gene transcription by thyroid hormone receptor β agonists in clinical development for the treatment of non-alcoholic steatohepatitis (NASH). PLOS ONE, 15, e0240338. https://doi.org/10.1371/journal.pone.0240338

Petroni, M. L., Brodosi, L., Bugianesi, E., & Marchesini, G. (2021). Management of non-alcoholic fatty liver disease. BMJ, 372, m4747. https://doi.org/10.1136/bmj.m4747

Prikhodko, V. A., Bezborodkina, N. N., & Okovityi, S. V. (2022). Pharmacotherapy for non-alcoholic fatty liver disease: Emerging targets and drug candidates. Biomedicines, 10, Article 274. https://doi.org/10.3390/biomedicines10020274

Pu, S., Zhao, B., Jiang, Y., & Cui, X. (2025). Hypothyroidism/subclinical hypothyroidism and metabolic dysfunction-associated steatotic liver disease: Advances in mechanism and treatment. Lipids in Health and Disease. https://doi.org/10.1186/s12944-025-02474-0

Rubin, V. R., Bojanic, K., Smolic, M., Rubin, J., Tabll, A., & Smolic, R. (2021). An update on efficacy and safety of emerging hepatic antifibrotic agents. Journal of Clinical and Translational Hepatology, Article 000, 1–11. https://doi.org/10.14218/jcth.2020.00040

Sinha, R. A., Bruinstroop, E., & Yen, P. M. (2025). Actions of thyroid hormones and thyromimetics on the liver. Nature Reviews Gastroenterology & Hepatology, 22, 9–22. https://doi.org/10.1038/s41575-024-00991-4

Tanase, D. M., Gosav, E. M., Neculae, E., Costea, C. F., Ciocoiu, M., Hurjui, L. L., Tarniceriu, C. C., & Floria, M. (2020). Hypothyroidism-induced nonalcoholic fatty liver disease (HIN): Mechanisms and emerging therapeutic options. International Journal of Molecular Sciences, 21, 5927. https://doi.org/10.3390/ijms21165927

Viking Therapeutics, Inc. (2016). Safety and tolerability of VK2809 in patients with primary hypercholesterolemia and non-alcoholic fatty liver disease (NCT02927184). ClinicalTrials.gov. https://clinicaltrials.gov/ct2/show/NCT02927184

Viking Therapeutics, Inc. (2019). A study to assess the efficacy and safety of VK2809 for 52 weeks in subjects with biopsy proven NASH (NCT04173065). ClinicalTrials.gov. https://clinicaltrials.gov/ct2/show/NCT04173065

Zhao, M., Xie, H., Shan, H., Zheng, Z., Li, G., Li, M., & Hong, L. (2022). Development of thyroid hormones and synthetic thyromimetics in non-alcoholic fatty liver disease. International Journal of Molecular Sciences, 23, 1102. https://doi.org/10.3390/ijms23031102

Zhou, J., Sinha, R. A., & Yen, P. M. (2021). The roles of autophagy and thyroid hormone in the pathogenesis and treatment of NAFLD. Hepatoma Research. https://doi.org/10.20517/2394-5079.2021.82
